Page 45 - CIBER-BBN2016-ENG

Most relevant scientific articles
• Vila O.F., Garrido C., Cano I., Guerra-Rebollo M., Navarro M., Meca-Cortes O. et al. Real-time bioluminescence imaging of cell distribution, growth, and differentiation in a three-dimensional scaffold under interstitial perfusion for tissue engineering. Tissue Engineering - Part C: Methods. 2016;22(9):864-872.
• Sánchez-Purra M., Ramos V., Petrenko V.A., Torchilin V.P., Borros S. Double-targeted polymersomes and liposomes for multiple barrier crossing. International Journal of Pharmaceutics. 2016;511(2):946- 956.
• Jayaram D.T., Ramos-Romero S., Shankar B.H., Garrido C., Rubio N., Sánchez-Cid L. et al. In Vitro and in Vivo Demonstration of Photodynamic Activity and Cytoplasm Imaging through TPE Nanoparticles. ACS Chemical Biology. 2016;11(1):104-112.
• Duchi S., Ramos-Romero S., Dozza B., Guerra-Rebollo M., Cattini L., Ballestri M. et al. Development of near-infrared photoactivable phthalocyanine-loaded nanoparticles to kill tumor cells: An improved tool for photodynamic therapy of solid cancers. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(7):1885-1897.
• Oh S., Borros S. Mucoadhesion vs mucus permeability of thiolated chitosan polymers and their resulting nanoparticles using a quartz crystal microbalance with dissipation (QCM-D). Colloids and Surfaces B: Biointerfaces. 2016;147:434-441.
Highlights
The Cell Therapy group has continued working in the area of cell therapy against tumors. Random introduction of DNA sequences in the human genome is inherently dangerous due to the possibility
of mutating antioncogenes. To avoid this, we have used the CRISPR/Cas9 to generate therapeutic mesenchymal stem cells (MSCsTer) bearing the thymidine kinase gene in a specific location of the genome. Moreover, we have demonstrated that such cells have antiglioma therapeutic capacity, equivalent to the virally modified ones.
Since discovering that MSCsTer used against gliomas are not killed in vivo by the Ganciclovir treatment, we were forced to assume that their therapeutic effect was mediated by an exosome or exosome-like based mechanism. Therefore, during the past year we have initiated a project to facilitate large scale purification of extracellular vesicles for therapy.
A consequence of anti-replication therapy against tumors is the appearance of a pool of therapy resistant glioma stem cells, that we can detect and quantify by bioluminescence imaging, capable of recapitulating tumors upon release from therapy. We believe that these cells are the last resource of therapy resistance and, in consequence, have aimed the project on their eradication.
The team has been funded by: a MINECO project, a Retos Collaboration project with Instituto Químico de Sarria (Barcelona) and SAGETIS, the Cell Therapy Network (TERCEL) and by a CIBER “Transference” project. The group has collaborated with CIBER groups for Biomaterials for Regenerative Therapy (IBEC); Bioengineering and Tissue Regeneration (UMA-Bionand) and Nanostructured Surfaces and Nanoparticle (NFP-INA), as well as with the Cardiac Insuficiency and Regeneration Group Hospital Germans Trias i Pujol.
BBN
Research Groups 45